These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16227425)

  • 1. FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment.
    Wendling D; Blagosklonov O; Streit G; Lehuédé G; Toussirot E; Cardot JC
    Ann Rheum Dis; 2005 Nov; 64(11):1663-5. PubMed ID: 16227425
    [No Abstract]   [Full Text] [Related]  

  • 2. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
    Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha blockade in ankylosing spondylitis: a potent but expensive anti-inflammatory treatment or true disease modification?
    Van den Bosch F; De Keyser F; Mielants H; Veys EM
    Arthritis Res Ther; 2005; 7(3):121-3. PubMed ID: 15899063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 6. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
    Temel M; Atagündüz P; Direskeneli H
    Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
    [No Abstract]   [Full Text] [Related]  

  • 7. Early histology in ankylosing spondylitis related spondylodiscitis supports its inflammatory origin.
    Nikolaisen C; Nossent H
    Scand J Rheumatol; 2005; 34(5):396-8. PubMed ID: 16234189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching anti-TNF therapy in ankylosing spondylitis.
    Pradeep DJ; Keat AC; Gaffney K; Brooksby A; Leeder J; Harris C
    Rheumatology (Oxford); 2008 Nov; 47(11):1726-7. PubMed ID: 18782856
    [No Abstract]   [Full Text] [Related]  

  • 9. Physical therapy in anti-TNF treated patients with ankylosing spondylitis.
    Dubey SG; Leeder J; Gaffney K
    Rheumatology (Oxford); 2008 Jul; 47(7):1100-1. PubMed ID: 18495822
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
    Jois RN; Gaffney K; Keat A
    Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
    [No Abstract]   [Full Text] [Related]  

  • 11. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
    Hermann J; Müller T; Yazdani-Biuki B; Aringer M; Herold M; Ebner W; Ofner P; Graninger W
    Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
    [No Abstract]   [Full Text] [Related]  

  • 12. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    Sieper J; Rudwaleit M
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF inhibitors for ankylosing spondylitis in the real world.
    McVeigh CM; Bell AL; Cairns AP
    Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
    [No Abstract]   [Full Text] [Related]  

  • 14. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
    Montagna GL; Malesci D; Buono R; Valentini G
    Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
    Kain T; MacGregor D; Buchanan RR; de Jager JP; Schachna L
    Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
    [No Abstract]   [Full Text] [Related]  

  • 19. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
    Smith N; Gadsby K; Butt S; Deighton C
    Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.